SciBase receives US approval for Nevisense

SciBase today announces that the US Food and Drug Administration (FDA) has approved the Scibase Pre-Market Approval (PMA) for its product Nevisense. Nevisense is SciBase’s device for the early detection of malignant melanoma. With the approval, SciBase can now market and sell Nevisense in the US.SciBase has now received confirmation from the FDA that the Nevisense PMA has been approved. According to the letter from the FDA the device is:‘intended for use on cutaneous lesions with one or more clinical or historical characteristics of melanoma, when a dermatologists chooses to obtain